China Biologic Products (NASDAQ:CBPO) posted its earnings results on Monday. The biopharmaceutical company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.21, RTT News reports. China Biologic Products had a net margin of 27.71% and a return on equity of 8.81%. The firm had revenue of $135.70 million during the quarter. During the same quarter in the prior year, the firm earned $1.17 earnings per share. The business’s revenue for the quarter was up 12.7% on a year-over-year basis. China Biologic Products updated its FY19 guidance to $4.18-4.26 EPS.
NASDAQ CBPO traded down $2.53 on Monday, hitting $93.29. The company had a trading volume of 142,109 shares, compared to its average volume of 193,319. The stock has a market capitalization of $3.67 billion, a P/E ratio of 23.21, a PEG ratio of 4.95 and a beta of 1.26. The company’s fifty day moving average price is $94.67. China Biologic Products has a 12-month low of $60.08 and a 12-month high of $105.50.
Several brokerages recently commented on CBPO. Zacks Investment Research raised shares of China Biologic Products from a “strong sell” rating to a “hold” rating in a report on Monday, May 13th. BidaskClub raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, July 24th. Finally, ValuEngine lowered shares of China Biologic Products from a “buy” rating to a “hold” rating in a report on Saturday, June 1st. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. China Biologic Products has a consensus rating of “Hold” and an average price target of $78.00.
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.